15.07.2024 13:35:10
|
Lupin Divests U.S. Commercial Women's Health Specialty Business To Evofem Biosciences
(RTTNews) - Pharma major Lupin Ltd. announced Monday that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (EVFM), a U.S. biopharmaceutical company focused exclusively on Women's Health.
Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC (secnidazole) 2g oral granules.
This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Evofem Biosciences Incmehr Nachrichten
Keine Nachrichten verfügbar. |